Retatrutide, MOTS-c and KPV compared
A hormone receptor, a target inside the cell, a transporter across its boundary. The receiving end helps explain which experiment to examine.
Targets and experiments
I don't picture these compounds as three contestants in a race. Their interactions give them different experimental jobs. The retatrutide receptor paper, MOTS-c CK2 study and KPV uptake paper supply particularly concrete starting points.
| Compound | Receiving end studied | Experiment |
|---|---|---|
| Retatrutide | GIP, GLP-1 and glucagon receptors | Receptor structures and cell assays, followed by controlled human trials |
| MOTS-c | CK2, with different activity in muscle and fat | Cell-free target assays and mouse experiments |
| KPV | PepT1 carries the fragment into intestinal cells | Cell uptake and inflammatory signalling, plus mouse colitis |
These are different kinds of interaction. Retatrutide activates hormone receptors. CK2 is an intracellular molecular target; PepT1 transports small peptides across a cell boundary. A common ingredient category supplies very little of that information.
Measured endpoints
| Finding | Subjects and setting | Endpoint and limit |
|---|---|---|
| Retatrutide weight change | 338 adults in a 48-week Phase 2 trial | Mean weight loss of 24.2% at 12 mg versus 2.1% with placebo; longer outcomes remain open |
| MOTS-c blood association | 94 chronic hemodialysis patients | Weak association with death or non-fatal cardiovascular events; an observational result |
| MOTS-c movement | Young, middle-aged and old mice | Improved treadmill performance, grip and gait; human treatment benefit untested |
| KPV colitis response | Cultured cells and mice with induced colitis | Reduced inflammatory signalling and mouse disease severity; no human therapeutic result |
No honest percentage can combine those rows into an overall “best peptide.” Weight change, a blood association and mouse-colitis severity use different endpoints, populations and designs. I’d follow the target through to the endpoint: what changed in the tissue, and what was then measured in the animal or person?
Safety, exposure and approval
Retatrutide's human trials recorded gastrointestinal effects and a dose-dependent pulse increase. Its early human study also measured an approximately six-day half-life. Comparable validated human exposure data are missing for MOTS-c and KPV, so their shorter lists of recorded harms provide little comfort.
All three remain unapproved for human use in the record here. Retatrutide remains investigational in Phase 3; MOTS-c and KPV remain research-only. KPV's carrier experiments add a particularly concrete uncertainty: a result with a protected formulation cannot establish what free peptide would do in a person.
The questions therefore stay attached to the compounds. Retatrutide needs longer clinical outcomes. MOTS-c needs a human treatment test. KPV needs human delivery, efficacy and safety evidence. A larger reputation cannot supply any of those missing measurements.